Repeating Trend, Cashing-Out

Once again, there’s a repeating trend of (potential) reversal.

This time, it’s biotech, specifically CRISPR Therapeutics, CRSP.

Before we get into it, a point of housekeeping; SOXS-23-10, has been closed, exited at SOXS 8.43; loss is manageable at -2.9% (not advice, not a recommendation).

CRSP, Market Proxy

CRSP, is being used as the proxy for biotech as it’s number five in market cap at this link.

However, the first two IMGN, and MRTX, are buyout (acquisition) candidates, eventually to be removed, making CRSP, number three with no additions.

Set-Ups That Repeat

Market behaviors repeat. Set-Ups repeat. The title above, was from a post over two years ago, link here.

Taking a look at CRSP, we have the same pattern.

CRISPR Therapeutics CRSP, Weekly

The volume spike for the week, is the largest ever; ergo, someone is selling.

From a CRSP, price action catalyst and news standpoint, the link is here.

This coming Wednesday, is the Fed interest rate announcement, link here.

Wyckoff said, ‘somebody always knows something and that “something”, shows up on the tape’.

It’s likely those that know, are cashing out ahead of the meeting (not advice, not a recommendation).

Positioning

If it’s presented on this site, a position has already been established or it’s in preparation for entry.

So, it is with biotech.

A biotech short was opened this past Friday via LABD with two entries: LABD 13.93 and LABD 14.17.

Trade is labeled, LABD-23-16

Hard Stop @ LABD 13.82, for a combined (both entries) risk of 0.23-pts/share (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279